Difference between revisions of "Apocrine carcinoma of the breast"

Jump to navigation Jump to search
Line 66: Line 66:
*ER -ve.  
*ER -ve.  
*PR -ve.
*PR -ve.
*often Her2 -ve


Notes
Notes
Line 73: Line 74:
**May respond to treatments targeting the androgen receptor<ref>{{Cite journal  | last1 = Safarpour | first1 = D. | last2 = Tavassoli | first2 = FA. | title = A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. | journal = Arch Pathol Lab Med | volume =  | issue =  | pages =  | month = Oct | year = 2014 | doi = 10.5858/arpa.2014-0122-RA | PMID = 25310144 }}
**May respond to treatments targeting the androgen receptor<ref>{{Cite journal  | last1 = Safarpour | first1 = D. | last2 = Tavassoli | first2 = FA. | title = A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. | journal = Arch Pathol Lab Med | volume =  | issue =  | pages =  | month = Oct | year = 2014 | doi = 10.5858/arpa.2014-0122-RA | PMID = 25310144 }}
</ref>
</ref>
**Be carefull when reading the literature in this area - is the author discussing 'molecular apocrine', 'IHC apocrine' or 'morphologic apocrine' carcinoma.  Many ductal carcinomas, NOS will show AR positivity.


==See also==
==See also==
653

edits

Navigation menu